Ultragenyx Pharmaceutical | RARE - Przychody Ze Sprzedaży





Obroty Zmiana Data
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Agios Pharmaceuticals USD 19.97M 7.07M 2025-12
Alnylam Pharmaceuticals USD 1.1B 150M 2025-12
BioCryst Pharmaceuticals USD 406.56M 247.16M 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Insmed USD 263.8M 121.8M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
Karyopharm Therapeutics USD 34.08M 3.54M 2025-12
Kyowa Hakko Kirin JPY 147.38B 28.58B 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
Moderna USD 678M 342M 2025-12
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
PTC Therapeutics USD 164.7M 46.3M 2025-12
Puma Biotechnology USD 80.54M 33.46M 2024-09
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Sarepta Therapeutics USD 442.9M 43.5M 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Vertex Pharmaceuticals USD 3.19B 110M 2025-12
Xoma USD 25K 5M 2024-09